About

Mark C. Schneyer has served as ACADIA's Executive Vice President and Chief Financial Officer since December 2021. He joined the company in May 2020 as Senior Vice President, Business Development and Chief Business Officer and served as interim CFO from September to December 2021. He oversees strategic finance, investor relations, accounting, business development, information technology and technical operations. Before ACADIA he was Vice President, Business Development for Pfizer's Upjohn division and spent nearly a decade in Pfizer's Worldwide Business Development organization, following 14 years as an investment banker at Lazard. He earned a B.S. in economics from the Wharton School of the University of Pennsylvania.

Roles

Acadia Pharmaceuticals Inc.
Executive Vice President, Chief Financial Officer · Current role
December 2021–present
ACADIA Pharmaceuticals
Executive Vice President and Chief Financial Officer
December 2021 - present
ACADIA Pharmaceuticals
Interim Chief Financial Officer
September 2021 - December 2021
ACADIA Pharmaceuticals
Senior Vice President, Business Development and Chief Business Officer
May 2020 - December 2021
Pfizer Inc.
Vice President, Business Development (Upjohn division)
2019 - May 2020
Pfizer Inc.
Worldwide Business Development, various roles
2011 - 2019
Lazard
Investment banker
1996 - 2010

Fixed Compensation

FY 2025
Salary
$546,428
ComponentAnnual base salary earned in FY2025
All other compensation
$28,174
Component401(k) match, insurance premiums, and other perquisites
Total compensation
$3,119,408

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$303,341
Target Opportunity
PlanAnnual cash bonus under the corporate incentive plan

Stock awards

Stock awards
$1,121,727
FormRSUs and PSUs, ASC 718 grant-date fair value
Option awards
$1,119,738
FormStock options, ASC 718 grant-date fair value

Also at Acadia Pharmaceuticals Inc.

Related

See how VectorShift works for your firm

Request Demo